Literature DB >> 19654111

Factors affecting matrix metalloproteinase-8 levels in the vaginal and cervical fluids in the first and second trimester of pregnancy.

Leena Rahkonen1, Eeva-Marja Rutanen, Leila Unkila-Kallio, Mika Nuutila, Pekka Nieminen, Timo Sorsa, Jorma Paavonen.   

Abstract

BACKGROUND: Cervical ripening during pregnancy resembles an inflammatory process. Matrix metalloproteinases (MMPs), particularly MMP-8, have been linked to inflammatory processes. We studied the concentrations of, and factors associated with, MMP-8 in the lower genital tract fluids in the first and second trimesters.
METHODS: In a prospective population-based cohort study, vaginal and cervical swab samples were obtained from 2130 unselected pregnant women undergoing their first and second trimester ultrasound screening. MMP-8 was determined by immunofluorometric assay. Use of antibiotics, history of vaginal bleeding, and history of sexual intercourse were recorded on both occasions. Vaginal smears were obtained for Gram-staining and leukocyte counting. Cervical length was measured by ultrasonography. The main outcome measures were MMP-8 concentrations in the vagina and cervix.
RESULTS: The median (range) MMP-8 concentrations in vaginal and cervical samples were 107.4 microg/l (undetectable-2406.6 microg/l) and 318.3 microg/l (0.1-2074.6 microg/l), respectively, in the first trimester, and 112.5 microg/l (undetectable-2093.4 microg/l) and 344.8 microg/l (0.4-1783.5 microg/l), respectively, in the second trimester. Multiparity and vaginal leukocytosis were both associated with increased MMP-8 concentrations in vaginal and cervical samples in both trimesters. Bacterial vaginosis (BV) was associated with increased vaginal and cervical MMP-8 in the first trimester, but only with increased vaginal MMP-8 in the second trimester. A history of sexual intercourse (in the previous 48 h) was associated with lower MMP-8 concentrations in cervical samples in both trimesters.
CONCLUSIONS: MMP-8 concentrations were lower in vaginal samples than in cervical samples, and no difference was found between the first and second trimesters. Multiparity, BV and an elevated leukocyte count in the vagina were associated with increased MMP-8 concentrations. Sexual intercourse had an opposite effect. The study suggests that MMP-8 is a physiologic constituent in lower genital tract fluids, where it may be involved in host response to inflammatory and infectious processes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19654111     DOI: 10.1093/humrep/dep284

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  12 in total

1.  Comparison of rapid MMP-8 and interleukin-6 point-of-care tests to identify intra-amniotic inflammation/infection and impending preterm delivery in patients with preterm labor and intact membranes.

Authors:  Piya Chaemsaithong; Roberto Romero; Nikolina Docheva; Noppadol Chaiyasit; Gaurav Bhatti; Percy Pacora; Sonia S Hassan; Lami Yeo; Offer Erez
Journal:  J Matern Fetal Neonatal Med       Date:  2017-03-01

2.  Cervicovaginal Fluid Acetate: A Metabolite Marker of Preterm Birth in Symptomatic Pregnant Women.

Authors:  Emmanuel Amabebe; Steven Reynolds; Victoria Stern; Graham Stafford; Martyn Paley; Dilly O C Anumba
Journal:  Front Med (Lausanne)       Date:  2016-10-10

3.  Association Study between the Polymorphisms of Matrix Metalloproteinase (MMP) Genes and Idiopathic Recurrent Pregnancy Loss.

Authors:  Han Sung Park; Ki Han Ko; Jung Oh Kim; Hui Jeong An; Young Ran Kim; Ji Hyang Kim; Woo Sik Lee; Nam Keun Kim
Journal:  Genes (Basel)       Date:  2019-05-07       Impact factor: 4.096

4.  Impact of preconception vaginal microbiota on women's risk of spontaneous preterm birth: protocol for a prospective case-cohort study.

Authors:  Erica M Lokken; Kishorchandra Mandaliya; Sujatha Srinivasan; Barbra A Richardson; John Kinuthia; Sophia Lannon; Walter Jaoko; Hudson Alumera; Arthur Kemoli; Emily Fay; G John-Stewart; David N Fredricks; R Scott McClelland
Journal:  BMJ Open       Date:  2020-02-25       Impact factor: 2.692

5.  Vaginal Biomarkers That Predict Cervical Length and Dominant Bacteria in the Vaginal Microbiomes of Pregnant Women.

Authors:  Steven S Witkin; Antonio F Moron; Benjamin J Ridenhour; Evelyn Minis; Alan Hatanaka; Stephanno G P Sarmento; Marcelo S Franca; Francisco H C Carvalho; Tatiana K Hamamoto; Rosiane Mattar; Ester Sabino; Iara M Linhares; Marilza V C Rudge; Larry J Forney
Journal:  mBio       Date:  2019-10-22       Impact factor: 7.867

6.  The Impacts of Fish Oil and/or Probiotic Intervention on Low-Grade Inflammation, IGFBP-1 and MMP-8 in Pregnancy: A Randomized, Placebo-Controlled, Double-Blind Clinical Trial.

Authors:  Noora Houttu; Kati Mokkala; Ella Koivuniemi; Outi Pellonperä; Juuso Juhila; Timo Sorsa; Kirsi Laitinen
Journal:  Biomolecules       Date:  2020-12-22

7.  Matrix metalloproteinases in a sea urchin ligament with adaptable mechanical properties.

Authors:  Ana R Ribeiro; Alice Barbaglio; Maria J Oliveira; Cristina C Ribeiro; Iain C Wilkie; Maria D Candia Carnevali; Mário A Barbosa
Journal:  PLoS One       Date:  2012-11-16       Impact factor: 3.240

8.  HIV inhibition by lactobacilli: easier in a test tube than in real life.

Authors:  Steven S Witkin; Iara M Linhares
Journal:  MBio       Date:  2015-10-06       Impact factor: 7.867

9.  Influence of vaginal bacteria and D- and L-lactic acid isomers on vaginal extracellular matrix metalloproteinase inducer: implications for protection against upper genital tract infections.

Authors:  Steven S Witkin; Helena Mendes-Soares; Iara M Linhares; Aswathi Jayaram; William J Ledger; Larry J Forney
Journal:  mBio       Date:  2013-08-06       Impact factor: 7.867

10.  Identifying metabolite markers for preterm birth in cervicovaginal fluid by magnetic resonance spectroscopy.

Authors:  Emmanuel Amabebe; Steven Reynolds; Victoria L Stern; Jennifer L Parker; Graham P Stafford; Martyn N Paley; Dilly O C Anumba
Journal:  Metabolomics       Date:  2016-03-08       Impact factor: 4.290

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.